Slow-Titration Protocol: Conservative Escalation for Nausea-Prone Users The Phase 2 trial protocol explicitly allowed prescribers to delay or skip dose escalation at physician discretion for participants who did not tolerate the protocol-specified increase (Jastreboff et al., NEJM 2023, Supplementary Appendix)
Running viability, cytotoxicity, and apoptosis as separate assays on separate plates means more sample, more time and more variability between measurements
It is worth noting that while we observed significant improvements in several markers, we did not find significant differences in total oxidant capacity or total antioxidant capacity between the groups
Additionally, retail pharmacies often provide counseling support, insurance processing, and promotional discounts, which further drive adoption and sustained use of GLP-1 therapies